NCT06828341

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 3 (estimated)
• Sponsor: JIANG LONGWEI · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if allogeneic CAR-T cells can treat patients with advanced gliomas. The main questions it aims to answer are: Evaluate the safety of allogeneic CAR-T cells in the treatment of advanced gliomas. To evaluate the effectiveness of allogeneic CAR-T cells in the treatment of advanced gliomas and to study its immunological properties in patients.

Detailed description

In this open, single-armed study, selected patients with advanced gliomas confirmed by Histopathology will be received allogeneic CAR-T cells treatment. First, their tumor specimen will be test to evaluate the expression of CD70.The patients with positive CD70 expression will be in enrolled.Then they will be received allogeneic CAR-T cells infusion cultured from heathy adults.

Conditions

• Gliomas

Interventions

Type	Name	Description
BIOLOGICAL	CAR-T	allogeneic CAR-T targeting CD70 that cultured from heathy adults.

Timeline

• Start date: 2024-06-13
• Primary completion: 2024-07-06
• Completion: 2026-06-30
• First posted: 2025-02-14
• Last updated: 2025-02-14

Locations

1 site across 1 country: China